Photo by mattreames from unsplash
MEF2D fusions, a recurrent feature in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), are associated with poor prognosis. Zhang and colleagues dissect the molecular mechanisms underlying the pathogenic function of the… Click to show full abstract
MEF2D fusions, a recurrent feature in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), are associated with poor prognosis. Zhang and colleagues dissect the molecular mechanisms underlying the pathogenic function of the MEF2D-HNRNPUL1 fusion, revealing that it impairs B-cell development. The authors also show that the HDAC inhibitor panobinostat in combination with chemotherapy improves overall survival in a murine model, suggesting a potential targeted intervention for BCP-ALL bearing MEF2D fusions.
Journal Title: Blood
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!